Akron Children's Logo
Skip to main content
Close Tools Menu Icon

Operator:

330-543-1000

Questions or Referrals:
ASK CHILDREN‘S

Close Phone Menu Icon
Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

STOP2 – Standardized Treatment of Pulmonary Exacerbations

Full IRB Study Title:
Standardized Treatment of Pulmonary Exacerbation II (STOP2) Protocol No: STOP2-IP-15

IRB Study ID: 966544-18

For complete study information, view the study on clinicaltrials.gov

Study Sponsor:

CFFT Therapeutics Development Network Coordinating Center (TDNCC)

Who May Qualify:

Patients with Cystic Fibrosis ≥ 18 years of age planned to initiate intravenous (IV) antibiotics for a pulmonary exacerbation

Who Does NOT Qualify:

Patients who have been treated with IV antibiotics within 6 weeks prior to Visit 1

Lead Investigator

Gregory Omlor

Gregory Omlor, MD, FAAP

Director, Lewis H Walker CF Center; Pediatric Pulmonologist; Pediatric Sleep Medicine


Lewis H. Walker, MD, Cystic Fibrosis CenterRobert T. Stone, MD, Respiratory CenterPediatric Sleep Medicine

More about this provider

Back to top of page

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.